Eosinophilic reactive airways disease after immune checkpoint inhibitor treatment
Respirology Case Reports · 2024-09 · 12 (9)
DOI: 10.1002/rcr2.70022 ↗Kurz gefasst
Fallbericht in der Zeitschrift Respirology Case Reports, online erschienen am 08.09.2024. Verfasst von Parker Cordial und 3 weiteren Autor:innen. Beteiligte Einrichtung: Internal Medicine The Ohio State University Wexner Medical Center Columbus Ohio USA. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Immune checkpoint inhibitors (ICI) are increasingly utilized as first‐line treatment for many solid tumour malignancies. One downside of ICI therapy is autoimmune‐mediated organ inflammation, or immune‐related adverse events (irAE). ICI‐related pneumonitis, or non‐infectious inflammation of the lung, is a well‐described irAE. While guidelines surrounding ICI‐related pneumonitis are well established, other ICI‐related pulmonary toxicities, including reactive airways disease, are rarely described in the literature. Here, we present a series of patients without pre‐existing COPD or asthma who developed reactive airways disease with peripheral eosinophilia after ICI therapy and without radiographic evidence of pneumonitis. The patients were treated with typical therapies for reactive airways disease, including– inhaled steroids, bronchodilators, systemic steroids, and in one instance, dupilumab. All experienced symptomatic improvement with these therapies, enabling some of the patients to continue receiving ICI therapy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Internal Medicine The Ohio State University Wexner Medical Center Columbus Ohio USA.
- Division of Pulmonary, Critical Care and Sleep Medicine The Ohio State University Wexner Medical Center Columbus Ohio USA.
- Dorothy M. Davis Heart and Lung Research Institute The Ohio State Wexner Medical Center Columbus Ohio USA.
ORCID-Profile: Jeffrey C Horowitz, Kevin Ho
Zitieren
APA
Cordial, P., Bentley, I. D., Horowitz, J. C., & Ho, K. (2024). Eosinophilic reactive airways disease after immune checkpoint inhibitor treatment. Respirology Case Reports, 12(9). https://doi.org/10.1002/rcr2.70022
Vancouver
Cordial P, Bentley ID, Horowitz JC, Ho K. Eosinophilic reactive airways disease after immune checkpoint inhibitor treatment. Respirology Case Reports. 2024;12(9). doi:10.1002/rcr2.70022
BibTeX
@article{Cordial2024,
author = {Cordial, Parker and Bentley, Ian D and Horowitz, Jeffrey C and Ho, Kevin},
title = {Eosinophilic reactive airways disease after immune checkpoint inhibitor treatment},
journal = {Respirology Case Reports},
year = {2024},
volume = {12},
number = {9},
doi = {10.1002/rcr2.70022}
}
EUVIMED